200 related articles for article (PubMed ID: 11082773)
1. Failure of local defense mechanisms in cystic fibrosis.
Proesmans M; De Boeck K
Acta Otorhinolaryngol Belg; 2000; 54(3):367-72. PubMed ID: 11082773
[TBL] [Abstract][Full Text] [Related]
2. Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies.
Kukavica-Ibrulj I; Levesque RC
Lab Anim; 2008 Oct; 42(4):389-412. PubMed ID: 18782827
[TBL] [Abstract][Full Text] [Related]
3. Familial concordance of phenotype and microbial variation among siblings with CF.
Picard E; Aviram M; Yahav Y; Rivlin J; Blau H; Bentur L; Avital A; Villa Y; Schwartz S; Kerem B; Kerem E
Pediatr Pulmonol; 2004 Oct; 38(4):292-7. PubMed ID: 15334505
[TBL] [Abstract][Full Text] [Related]
4. Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis.
Dorfman R; Taylor C; Lin F; Sun L; Sandford A; Paré P; Berthiaume Y; Corey M; Durie P; Zielenski J;
Pediatr Pulmonol; 2011 Apr; 46(4):385-92. PubMed ID: 20967843
[TBL] [Abstract][Full Text] [Related]
5. How mutant CFTR may contribute to Pseudomonas aeruginosa infection in cystic fibrosis.
Pier GB; Grout M; Zaidi TS; Goldberg JB
Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 2):S175-82. PubMed ID: 8876538
[TBL] [Abstract][Full Text] [Related]
6. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
[TBL] [Abstract][Full Text] [Related]
7. Introduction to section I: overview of approaches to study cystic fibrosis pathophysiology.
Clunes MT; Boucher RC
Methods Mol Biol; 2011; 742():3-14. PubMed ID: 21547723
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology and management of pulmonary infections in cystic fibrosis.
Gibson RL; Burns JL; Ramsey BW
Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
[TBL] [Abstract][Full Text] [Related]
9. Oxygen, cyanide and energy generation in the cystic fibrosis pathogen Pseudomonas aeruginosa.
Williams HD; Zlosnik JE; Ryall B
Adv Microb Physiol; 2007; 52():1-71. PubMed ID: 17027370
[TBL] [Abstract][Full Text] [Related]
10. Fcgamma receptor IIA genotype and susceptibility to P. aeruginosa infection in patients with cystic fibrosis.
De Rose V; Arduino C; Cappello N; Piana R; Salmin P; Bardessono M; Goia M; Padoan R; Bignamini E; Costantini D; Pizzamiglio G; Bennato V; Colombo C; Giunta A; Piazza A
Eur J Hum Genet; 2005 Jan; 13(1):96-101. PubMed ID: 15367919
[TBL] [Abstract][Full Text] [Related]
11. The approach to Pseudomonas aeruginosa in cystic fibrosis.
Bendiak GN; Ratjen F
Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
[TBL] [Abstract][Full Text] [Related]
12. Altered terminal glycosylation and the pathophysiology of CF lung disease.
Rhim AD; Stoykova LI; Trindade AJ; Glick MC; Scanlin TF
J Cyst Fibros; 2004 Aug; 3 Suppl 2():95-6. PubMed ID: 15463936
[TBL] [Abstract][Full Text] [Related]
13. Interaction between Pseudomonas aeruginosa and host defenses in cystic fibrosis.
Marshall BC; Carroll KC
Semin Respir Infect; 1991 Mar; 6(1):11-8. PubMed ID: 1909452
[TBL] [Abstract][Full Text] [Related]
14. Immunopathophysiologic mechanisms of cystic fibrosis lung disease.
Soferman R
Isr Med Assoc J; 2006 Jan; 8(1):44-8. PubMed ID: 16450752
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary infection in mild variant cystic fibrosis: implications for care.
Lording A; McGaw J; Dalton A; Beal G; Everard M; Taylor CJ
J Cyst Fibros; 2006 May; 5(2):101-4. PubMed ID: 16426904
[TBL] [Abstract][Full Text] [Related]
16. Role of the cystic fibrosis transmembrane conductance regulator in internalization of Pseudomonas aeruginosa by polarized respiratory epithelial cells.
Darling KE; Dewar A; Evans TJ
Cell Microbiol; 2004 Jun; 6(6):521-33. PubMed ID: 15104594
[TBL] [Abstract][Full Text] [Related]
17. Pseudomonas respiratory infection in cystic fibrosis: a possible defect in opsonic IgG antibody?
Fick RB; Reynolds HY
Bull Eur Physiopathol Respir; 1983; 19(2):151-61. PubMed ID: 6871494
[TBL] [Abstract][Full Text] [Related]
18. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary host defense: defects that lead to chronic inflammation of the airway.
Hornick DB
Clin Chest Med; 1988 Dec; 9(4):669-78. PubMed ID: 3148383
[TBL] [Abstract][Full Text] [Related]
20. CFTR-dependent susceptibility of the cystic fibrosis-host to Pseudomonas aeruginosa.
Grassmé H; Becker KA; Zhang Y; Gulbins E
Int J Med Microbiol; 2010 Dec; 300(8):578-83. PubMed ID: 20951085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
